Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 6/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049176 | 1.00 | POLB (0.57) | POLBTDP1ALDH1A1HCAR3CASP6 | |
| SCHEMBL17049177 | 1.00 | POLB (0.57) | POLBTDP1ALDH1A1HCAR3CASP6 | |
| SCHEMBL7472334 | 0.87 | POLB (0.60) | POLBTDP1ALDH1A1LMNAMAPT | |
| SCHEMBL19055417 | 0.87 | POLB (0.60) | POLBTDP1ALDH1A1LMNAMAPT | |
| SCHEMBL7473306 | 0.82 | POLB (0.45) | POLBTDP1ALDH1A1TSHRMAPT | |
| SCHEMBL17049181 | 0.81 | POLB (0.46) | POLBTDP1ALDH1A1TSHRLMNA | |
| SCHEMBL18371960 | 0.81 | POLB (0.46) | POLBTDP1ALDH1A1TSHRLMNA | |
| SCHEMBL18371959 | 0.81 | POLB (0.46) | POLBTDP1ALDH1A1TSHRLMNA | |
| SCHEMBL7476840 | 0.81 | POLB (0.46) | POLBTDP1ALDH1A1TSHRLMNA | |
| SCHEMBL17049183 | 0.81 | POLB (0.46) | POLBTDP1ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-10-15 | — | — | US | disclosed |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-09-20 | — | — | US | disclosed |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | LYCERA CORPORATION | 2018-07-26 | — | — | US | disclosed |
| US-9896441-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-29 | — | — | US | disclosed |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-01-12 | — | — | US | disclosed |
| EP-3110429-A1 | ADOPTIVE CELLULAR THERAPY USING AN AGONIST OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMA & RELATED THERAPEUTIC METHODS | Lycera Corporation (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015131035-A1 | ADOPTIVE CELLULAR THERAPY USING AN AGONIST OF RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR GAMMA & RELATED THERAPEUTIC METHODS | LYCERA CORPORATION (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180265502-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | POLB 4352/4885TDP1 4596/4885ALDH1A1 602/4885 |
| US-10364237-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | POLB 4519/4885TDP1 4421/4885ALDH1A1 762/4885 |
| US-20170007686-A1 | Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods | RORC, RORA, RORB | POLB 3272/4885TDP1 4145/4885ALDH1A1 784/4885 |
| US-10442798-B2 | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORA, RORC, RORB | POLB 4519/4885TDP1 4421/4885ALDH1A1 762/4885 |
| US-20170183331-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | POLB 4352/4885TDP1 4596/4885ALDH1A1 602/4885 |
| US-20180208587-A1 | TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | POLB 4352/4885TDP1 4596/4885ALDH1A1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.